Aimovig (erenumab-aooe) - Amgen
Ubrelvy (ubrogepant) - AbbVie
Vyepti (eptinezumab-jjmr) - Teva, Lundbeck
Emgality (galcanezumab-gnlm) - Eli Lilly, Daiichi Sankyo
Botox (onabotulinumtoxin A) - GSK, AbbVie, Healis Therap
Ajovy (fremanezumab-vfrm) - Teva
Qulipta (atogepant) - AbbVie
Nurtec ODT (rimegepant ODT) - Pfizer
Migraine Medication Effects on Urinary Symptoms (clinicaltrials.gov) - Oct 22, 2026 - P=N/A | N=200 | Enrolling by invitation | Sponsor: The Cleveland Clinic | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: May 2026 ➔ Jun 2027 
Trial completion date • Trial primary completion date • CNS Disorders • Interstitial Cystitis • Migraine • Musculoskeletal Pain • Overactive Bladder • Pain
http://clinicaltrials.gov/ct2/show/NCT06212661
 
Oct 22, 2026
 
Prev Next